Oculis

2024 saw significant advancements in ophthalmology, including FDA approvals, AI and VR in healthcare, sustainable surgical practices, and new treatments for dry eye and retinal diseases. Clinical trials and patient understanding of conditions like dry eye disease also progressed.

Ophthalmology Times reflects on 2024's key topics: AI in healthcare, VR for medical collaboration, operating room efficiency, sustainability in surgeries, and advancements in treatments like biosimilars and dry eye therapies. FDA approvals and clinical trials highlight ongoing progress in ophthalmology.

Focke Ziemssen, Michelle Sylvanowicz, Winfried M. Amoaku, Tariq Aslam, Bora Eldem, Robert P. Finger, Richard P. Gale, Laurent Kodjikian, Jean-François Korobelnik, Xiaofeng Lin, Anat Loewenstein, Paul Mitchell, Moira Murphy, David R. Owens, Nick Parker, Ian Pearce, Francisco J. Rodríguez, Jude Stern, S. James Talks, David T. Wong, Tien Yin Wong, and Jane Barratt disclose various financial interests including travel grants, personal fees, advisory board memberships, speaker fees, research sponsorship, and consulting roles with companies such as Allergan, AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Janssen, Novartis, Novo Nordisk, Merck, Regeneron, Roche, Sanofi, and others.

DelveInsight's report on Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2034 covers historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, market size, and key companies in the US, EU5, and Japan. The market size in the US was ~USD 1,800 million in 2023, expected to increase by 2034. Key companies include Taiwan Liposome Company (TLC), Teikoku Pharma, Novartis, and others. Emerging therapies include TLC590, TPU-006, Libvatrep, and more.

European healthtech companies raised $3.4 billion in 2024, driving innovations in AI, telemedicine, digital therapies, and wearables to enhance personalized and efficient healthcare by 2025.

Oculis announces Q3 2024 results, highlighting progress in its OCS-01 DIAMOND Phase 3 program for DME and OCS-05 Phase 2 ACUITY trial for AON, with topline readout expected in December 2024. The company strengthened its leadership team and reported $125.0 million in cash, cash equivalents, and short-term investments as of September 30, 2024, enabling operations into 2H 2026.